Intranasal Epinephrine

About ARS Pharmaceuticals

ARS Pharmaceuticals is on a mission to transform the treatment of severe allergic reactions by developing needle-free, patient-friendly therapies. Its transformative achievement is the 2024 FDA approval of neffy®, the first needle-free epinephrine nasal spray, which directly tackles the underutilization of epinephrine due to fear, complexity, and portability issues with auto-injectors. The company's strategy is to commercialize neffy® in the substantial anaphylaxis market while advancing its intranasal platform into adjacent Type I hypersensitivity indications like urticaria, aiming to capture significant market share from entrenched auto-injector competitors.

Therapeutic Areas